Are the effects of blood pressure lowering treatment diminishing?: meta-regression analyses
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Previous studies have suggested that the effects of medical interventions tend to diminish over time. We investigated whether the effects of blood pressure lowering treatment on all-cause mortality and stroke have diminished over time. Methods: We conducted meta-regression analyses. We extracted the target trials from two recently published comprehensive systematic reviews and meta-analyses. Adopted variables were relative risk (RR) of all-cause mortality and stroke, trial start year, mean age, sample size, baseline systolic blood pressure (SBP), difference in attained SBP reduction between intervention groups and control groups (SBP difference), and regional dummies. We implemented single meta-regressions, in which the dependent variable was the log of RR and the explanatory variable was each of other adopted variables. We also conducted multiple meta-regressions, in which the dependent variable was the log of RR and explanatory variables were all of other adopted variables. Our variable of greatest interest was trial start year. Results: The included reviews assessed 85 trials with a total of 343,126 participants. Although trial start year was positively associated with the log of RR in the results of single meta-regressions, it lost significance in multiple meta-regressions for both allcause mortality and stroke. Conclusions: The effects of blood pressure lowering treatment on all-cause mortality and stroke have not diminished over time.
Abstract
Background: Previous studies have suggested that the effects of medical interventions tend to diminish over time. We investigated whether the effects of blood pressure lowering treatment on all-cause mortality and stroke have diminished over time. Methods: We conducted meta-regression analyses. We extracted the target trials from two recently published comprehensive systematic reviews and meta-analyses. Adopted variables were relative risk (RR) of all-cause mortality and stroke, trial start year, mean age, sample size, baseline systolic blood pressure (SBP), difference in attained SBP reduction between intervention groups and control groups (SBP difference), and regional dummies. We implemented single meta-regressions, in which the dependent variable was the log of RR and the explanatory variable was each of other adopted variables. We also conducted multiple meta-regressions, in which the dependent variable was the log of RR and explanatory variables were all of other adopted variables. Our variable of greatest interest was trial start year. Results: The included reviews assessed 85 trials with a total of 343,126 participants. Although trial start year was positively associated with the log of RR in the results of single meta-regressions, it lost significance in multiple meta-regressions for both allcause mortality and stroke. Conclusions: The effects of blood pressure lowering treatment on all-cause mortality and stroke have not diminished over time.
참고문헌 (31)
- Gehr BT, "The fading of reported effectiveness. A metaanalysis of randomised controlled trials", BMC Med Res Methodol, 6, pp.25~ (2006)
- Protzko J, "Psychological Science Under Scrutiny", pp.85~107 (2017), Wiley-Blackwell
- Baker R, "Inference for meta-analysis with a suspected temporal trend", Biom J, 52, pp.538~551 (2010)[DOI]
- Ioannidis JPA, "Evolution and translation of research findings : from bench to where", PLoS Clin Trials, 1, pp.e36~ (2006)[DOI]
- Dogo SH, "Sequential change detection and monitoring of temporal trends in random-effects meta-analysis", Res Synth Methods, 8, pp.220~235 (2017)[DOI]
- Fanshawe TR, "A large-scale assessment of temporal trends in meta-analyses using systematic review reports from the Cochrane library", Res Synth Methods, 8, pp.404~415 (2017)[DOI]
- Trikalinos TA, "Publication bias in metaanalysis:prevention, assessment and adjustments", pp.241~259 (2005), Wiley-Blackwell
- Johnsen TJ, "The effects of cognitive behavioral therapy as an anti-depressive treatment is falling : a meta-analysis", Psychol Bull, 141, pp.747~768 (2015)[DOI]
- Leucht S, "Putting the efficacy of psychiatric and general medicine medication into perspective : review of meta-analyses", Br J Psychiatry, 200, pp.97~106 (2012)[DOI]
- Janus Christian Jakobsen, "Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis", BMC Psychiatry, 17(1) (2017), Island Press[DOI]
- Andrea Cipriani, "Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis", The Lancet, 391(10128), pp.1357~1366 (2018), Elsevier BV[DOI]
- M R Law, "Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies", BMJ, 338(may19 1), pp.b1665~b1665 (2009), BMJ[DOI]
- Dena Ettehad, "Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis", The Lancet, 387(10022), pp.957~967 (2016), Elsevier BV[DOI]
- Mattias Brunström, "Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels", JAMA Internal Medicine, 178(1), pp.28~ (2018), American Medical Association (AMA)[DOI]
- Folkert W. Asselbergs, "Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria", Circulation, 110(18), pp.2809~2816 (2004), Ovid Technologies (Wolters Kluwer Health)[DOI]
- Lennart Hansson, "The BBB Study: The Effect of Intensified Antihypertensive Treatment on the Level of Blood Pressure, Side-Effects, Morbidity and Mortality in “Well-Treated” Hypertensive Patients", Blood Pressure, 3(4), pp.248~254 (2009), Informa UK Limited[DOI]
- A. Amery, "Antihypertensive Therapy in Patients above Age 60 Years (Fourth Interim Report of the European Working Party on High Blood Pressure in Elderly: EWPHE)", Clinical Science, 55(s4), pp.263s~270s (1978), Portland Press Ltd.[DOI]
- Stephan Lüders, "The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure – a prospective, randomized, controlled prevention trial of the German Hypertension League", Journal of Hypertension, 26(7), pp.1487~1496 (2008), Ovid Technologies (Wolters Kluwer Health)[DOI]
- Helgeland A, "Treatment of mild hypertension : a five year controlled drug trial", The Oslo study Am J Med, 69, pp.725~732 (1980)
- JATOS Study Group, "Principal Results of the Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS)", Hypertension Research, 31(12), pp.2115~2127 (2008), Japanese Society of Hypertension[DOI]
- Sun M, "Prevention and treatment of stroke after hypertension for ten years in Hunan Province", Zhonghua Nei Ke Za Zhi, 36, pp.312~314 (1997)
- "WebPlotDigitizer" (2018)[URL]
- Edmund J. Lewis, "The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy", New England Journal of Medicine, 329(20), pp.1456~1462 (1993), Massachusetts Medical Society[DOI]
- Black HR, "Clinical trials in hypertension" (2001), Marcel Dekker Inc
- Harbord RM, "Meta-regression in Stata", Stata J, 8, pp.493~519 (2008)
- The ONTARGET Investigators, "Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events", New England Journal of Medicine, 358(15), pp.1547~1559 (2008), Massachusetts Medical Society[DOI]
- Salim Yusuf, "Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events", New England Journal of Medicine, 359(12), pp.1225~1237 (2008), Massachusetts Medical Society[DOI]
- The SPS3 Study Group, "Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial", The Lancet, 382(9891), pp.507~515 (2013), Elsevier BV[DOI]
- PROGRESS Collaborative Group, "Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack", The Lancet, 358(9287), pp.1033~1041 (2001), Elsevier BV[DOI]
- Yusuf S, "Irbesartan in Patients with Atrial Fibrillation", New England Journal of Medicine, 364(10), pp.928~938 (2011), Massachusetts Medical Society[DOI]
- Costas Thomopoulos, "Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials", Journal of Hypertension, 32(12), pp.2285~2295 (2014), Ovid Technologies (Wolters Kluwer Health)[DOI]